Announced details
AUROC 0.898 (95% confidence interval: 0.895–0.901)
Among those in the top 1% by prediction score, 28.3% were SAS patients actually receiving CPAP treatment
Among those in the top 10% by prediction score, 10.3% were SAS patients actually receiving CPAP treatment
Number of prediction variables: 279
A joint research group comprising JMDC, OMRON Corporation and the University of Tsukuba. JMDC and the University of Tsukuba have a joint research agreement, while OMRON is responsible for device-data integration and clinical advice.
OMRON Corporation: Headquarters in Shimogyo-ku, Kyoto; President and CEO Tsujinaga Junta (辻永順太). OMRON operates businesses in industrial automation, healthcare, social systems, electronic components and data solutions. Founded in 1933, it has approximately 26,000 employees worldwide and operates in more than 130 countries., National University Corporation, University of Tsukuba: Located in Tsukuba, Ibaraki Prefecture; President Nagata Kyosuke (永田恭介). A comprehensive university established in October 1973.
Scope: approximately 1.86 million Pep Up users and approximately 18.69 million records in total (January 2022 to July 2024, at 11 time points)
The disclosure states that the parties aim to deploy the prediction service in society and pursue business co-creation, but the specific impact on financial results is not disclosed
The company does not address Contract Value / Offering price.
International academic journal Sleep and Breathing
PubMed (paper URL provided)
AMED Moonshot Research and Development Program (JP21zf0127005)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Pep Up (health management platform), AI model for predicting the risk of sleep apnea syndrome (SAS), Prediction service (planned future deployment) |
| Counterparty | OMRON Corporation, National University Corporation University of Tsukuba |
| Counterparty overview | OMRON Corporation: Headquarters in Shimogyo-ku, Kyoto; President and CEO Tsujinaga Junta (辻永順太). OMRON operates businesses in industrial automation, healthcare, social systems, electronic components and data solutions. Founded in 1933, it has approximately 26,000 employees worldwide and operates in more than 130 countries., National University Corporation, University of Tsukuba: Located in Tsukuba, Ibaraki Prefecture; President Nagata Kyosuke (永田恭介). A comprehensive university established in October 1973. |
| Relationship with the Company | A joint research group comprising JMDC, OMRON Corporation and the University of Tsukuba. JMDC and the University of Tsukuba have a joint research agreement, while OMRON is responsible for device-data integration and clinical advice. |
| Contract Date | Term of the joint research agreement: from 1 April 2025 (the agreement date is not specified) |
| Applicable area | Screening for sleep apnea syndrome (SAS), Preventive medicine, Referral for further testing and treatment, Potential future expansion into cerebrocardiovascular events, lifestyle-related diseases and mental health disorders |
| Location scale | Scope: approximately 1.86 million Pep Up users and approximately 18.69 million records in total (January 2022 to July 2024, at 11 time points) |
| Quantitative Effects | AUROC 0.898 (95% confidence interval: 0.895–0.901), Among those in the top 1% by prediction score, 28.3% were SAS patients actually receiving CPAP treatment, Among those in the top 10% by prediction score, 10.3% were SAS patients actually receiving CPAP treatment, Number of prediction variables: 279 |
| Impact on Business Performance | The disclosure states that the parties aim to deploy the prediction service in society and pursue business co-creation, but the specific impact on financial results is not disclosed |
| Source | International academic journal Sleep and Breathing, PubMed (paper URL provided), AMED Moonshot Research and Development Program (JP21zf0127005) |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To identify people at high risk of SAS, which is easily overlooked because it often produces few noticeable symptoms, while limiting the need for special tests and additional burden, and connect them with appropriate testing and treatment.